Biofrontera AG (BFRA)
Stock Price:
$6.00 USD
-0.19 (-3.07%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
134.55M |
| Revenue (ttm) |
35.13M |
| Net Income (ttm) |
-8.27M |
| Shares Out |
22.42M |
| EPS (ttm) |
-0.76 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 8, 2020 |
| Last Price |
$6.00 |
| Previous Close |
$6.19 |
| Change ($) |
-0.19 |
| Change (%) |
-3.07% |
| Day's Open |
6.30 |
| Day's Range |
5.60 - 6.43 |
| Day's Volume |
389 |
| 52-Week Range |
5.41 - 17.32 |
More Stats
| Market Cap |
134.55M |
| Enterprise Value |
163.70M |
| Earnings Date (est) |
Aug 27, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
22.42M |
| Float |
11.26M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.76 |
| FCF / Share |
-1.74 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
554 |
| Short Ratio |
0.26 |
| Short % of Float |
n/a |
| Beta |
1.13 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3.83 |
| PB Ratio |
30.95 |
| Revenue |
35.13M |
| Operating Income |
-19.11M |
| Net Income |
-8.27M |
| Free Cash Flow |
-38.94M |
| Net Cash |
-29.15M |
| Net Cash / Share |
-1.30 |
| Gross Margin |
84.41% |
| Operating Margin |
-54.39% |
| Profit Margin |
-23.50% |
| FCF Margin |
-110.84% |
| ROA |
-33.41% |
| ROE |
-115.17% |
| ROIC |
-12.20% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$10.11*
(68.50% upside)
Low
8.00
Current: 6.00
High
11.33
Target: 10.11
*Average 12-month USD price target from 3 stock analysts.
Financial Performance
Financial numbers in millions EUR.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 31.27 | 21.11 | 12.03 | 6.13 | 4.14 |
| Revenue Growth | 48.13% | 75.53% | 96.17% | 48.14% | - |
| Gross Profit | 26.39 | 16.66 | 10.31 | 4.48 | 2.90 |
| Operating Income | -17.01 | -17.51 | -15.01 | -9.38 | -10.23 |
| Net Income | -7.36 | -8.88 | -16.10 | -10.58 | -11.20 |
| Shares Outstanding | 44.63 | 44.24 | - | - | - |
| Earnings Per Share | -0.32 | -0.40 | -0.84 | -0.72 | -0.96 |
| Operating Cash Flow | -32.89 | -13.43 | -13.12 | -10.26 | -9.66 |
| Capital Expenditures | -1.76 | -0.51 | -0.38 | -0.46 | -0.17 |
| Free Cash Flow | -34.66 | -13.95 | -13.50 | -10.72 | -9.82 |
| Cash & Equivalents | 12.20 | 20.25 | 11.65 | 15.80 | 4.69 |
| Total Debt | 38.14 | 13.66 | 12.55 | 3.93 | 12.10 |
| Net Cash / Debt | -25.95 | 6.59 | -0.89 | 11.87 | -7.41 |
| Assets | 58.36 | 39.13 | 19.85 | 23.88 | 9.50 |
| Liabilities | 48.41 | 22.78 | 16.47 | 4.44 | 14.31 |
| Book Value | 9.96 | 16.36 | 3.38 | 15.84 | -4.81 |
Numbers in millions EUR, except per-share numbers.
Company Details
| Full Name |
Biofrontera AG |
| Country |
Germany |
| Employees |
160 |
| CEO |
Hermann Lübbert |
Stock Information
| Ticker Symbol |
BFRA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: BFRA |
| IPO Date |
February 14, 2018 |
Description
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.